Rockwell Medical Appoints New CMO, Elects Directors
Ticker: RMTI · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1041024
| Field | Detail |
|---|---|
| Company | Rockwell Medical, Inc. (RMTI) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
Related Tickers: RMTI
TL;DR
Rockwell Medical shakes up leadership with a new CMO and two board members.
AI Summary
Rockwell Medical, Inc. announced on December 10, 2024, the appointment of Dr. Robert L. Judd as Chief Medical Officer and the election of Ms. Karen L. King and Mr. David M. D. Smith to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, details of which are included in the filing.
Why It Matters
These executive and board changes could signal a strategic shift or renewed focus for Rockwell Medical, potentially impacting its future direction and operational strategies.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Rockwell Medical, Inc. (company) — Registrant
- Dr. Robert L. Judd (person) — Appointed Chief Medical Officer
- Ms. Karen L. King (person) — Elected to Board of Directors
- Mr. David M. D. Smith (person) — Elected to Board of Directors
- December 10, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Robert L. Judd has been appointed as the new Chief Medical Officer.
Who were elected to the Board of Directors?
Ms. Karen L. King and Mr. David M. D. Smith were elected to the Board of Directors.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is December 10, 2024.
What other information is disclosed regarding officers?
The filing also discloses compensatory arrangements for certain officers.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Filing Stats: 1,342 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2024-12-12 16:58:45
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 RMTI Nasdaq Capital Market Indicate
- $300,000 — i receives an annualized base salary of $300,000 (subject to adjustment), is eligible to
Filing Documents
- tm2430838d1_8k.htm (8-K) — 32KB
- tm2430838d1_ex10-1.htm (EX-10.1) — 151KB
- 0001104659-24-128064.txt ( ) — 392KB
- rmti-20241210.xsd (EX-101.SCH) — 3KB
- rmti-20241210_lab.xml (EX-101.LAB) — 33KB
- rmti-20241210_pre.xml (EX-101.PRE) — 22KB
- tm2430838d1_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 10, 2024, Rockwell Medical, Inc. (the "Company") announced the appointment of Jesse Neri as the Company's Senior Vice President and Chief Financial Officer effective immediately (the "Commencement Date"). Mr. Neri will also now serve as the Company's Principal Financial Officer. Mr. Neri, age 46, most recently served as the Company's Senior Vice President, Finance since October 2023 and principal accounting officer since January 2024. Prior to joining the Company, Mr. Neri was the Executive Director of Finance at Hemavant Sciences and Aruvant Sciences, clinical-stage biopharmaceutical companies that are members of the Roivant portfolio, from August 2021 to October 2023. From May 2020 to August 2021, Mr. Neri was a self-employed consultant. Mr. Neri served as Senior Vice President of Finance at Zyla Life Sciences, a pharmaceutical company, from January 2020 to May 2020, as Vice President of Finance of Zyla from March 2019 to January 2020 and prior to that, as Executive Director, Financial Planning and Analysis and prior to that, as Senior Director of Financial Planning and Analysis. Prior to Zyla, Mr. Neri served as Vice President of Financial Planning and Analysis at Symphony Health Solutions. He started his career at Ellucian, a leading ERP software provider for higher education institutions, where he held various roles of increasing responsibility. Mr. Neri received a B.S., Business Administration in Finance from Villanova University and an M.B.A. from Drexel University LeBow School of Business. On October 16, 2023, in connection with Mr. Neri's commencement of employment, the Company entered into an employment agreement with Mr. Neri (the "Employment Agreement"). The Employment Agreement provides that Mr. Neri will serve as an at-will employee. Mr. Neri receives an annualized base salary of $3
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 10.1 Employment Agreement, dated as of October 16, 2023, between the Company and Jesse Neri. 104 Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROCKWELL MEDICAL, INC. Date: December 12, 2024 By: /s/ Mark Strobeck Mark Strobeck, Ph.D. President and Chief Executive Officer